Brief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
15/10/2026 13:49
BRIEF-Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome Oct 15 (Reuters) - Krystal Biotech, Inc. KRYS.O:
KRYSTAL BIOTECH ANNOUNCES POSITIVE CLINICAL DATA FOR NEW DERMATOLOGY PROGRAM KB113 DEMONSTRATING BROAD BASAL CELL CARCINOMA REGRESSION IN PATIENTS WITH GORLIN SYNDROME
KRYSTAL BIOTECH - OVER 80% OF BASAL CELL CARCINOMA LESIONS REGRESSED WITH KB113 IN GORLIN SYNDROME PATIENTS
KRYSTAL BIOTECH - KB113 INJECTIONS WELL TOLERATED WITH ONLY MILD TO MODERATE TRANSIENT ADVERSE EVENTS
KRYSTAL BIOTECH - SUBSTANTIAL REGRESSION OBSERVED IN NON-INJECTED LESIONS WITH KB113
KRYSTAL BIOTECH - INITIATES FDA DISCUSSIONS ON ADVANCED CLINICAL DEVELOPMENT OF KB113
Source text: ID:nGNXpj2LX
Further company coverage: KRYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion